Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 6/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MGLL | Q99685 | 2/20 | 0.47 |
| ▸ | CA4 | P22748 | 1/20 | 0.42 |
| ▸ | CA6 | P23280 | 1/20 | 0.42 |
| ▸ | CA5A | P35218 | 1/20 | 0.42 |
| ▸ | CA7 | P43166 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21371136 | 0.82 | ENPP2 (0.59) | ENPP2KDM4EALDH1A1MGLLCA4 | |
| SCHEMBL3913281 | 0.78 | ENPP2 (0.45) | ENPP2KDM4EALDH1A1MGLL | |
| Methane SCHEMBL3871182 | 0.76 | ENPP2 (0.44) | ENPP2KDM4EALDH1A1MGLL | |
| SCHEMBL789866 | 0.75 | ENPP2 (0.70) | ENPP2KDM4EALDH1A1MGLLCA4 | |
| SCHEMBL1275147 | 0.75 | NOS1 (0.42) | ALDH1A1CA7 | |
| SCHEMBL5049590 | 0.74 | MIF (0.48) | ENPP2KDM4EALDH1A1MGLL | |
| SCHEMBL670457 | 0.72 | HTR3E (0.43) | ENPP2KDM4EALDH1A1 | |
| SCHEMBL670458 | 0.72 | HTR3E (0.43) | ENPP2KDM4EALDH1A1 | |
| SCHEMBL7641392 | 0.72 | MEN1 (0.55) | ENPP2 | |
| SCHEMBL7641390 | 0.72 | MEN1 (0.55) | ENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | TANGO THERAPEUTICS, INC. | 2024-07-11 | — | — | US | disclosed |
| US-20230310634-A1 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF | IMMUNEXT INC (US) | 2023-10-05 | — | — | US | disclosed |
| EP-2729448-B1 | COMPOUNDS FOR THE TREATMENT OF HIV | GILEAD SCIENCES INC (US) | 2015-09-09 | — | — | EP | disclosed |
| WO-2015027222-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | NEUPHARMA, INC. (US) | 2015-02-26 | — | — | WO | disclosed |
| WO-2009067600-A2 | BIARYL PDE4 INHIBITORS FOR TREATING INFLAMMATION | DECODE GENETICS EHF (IS) | 2009-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230310634-A1 | ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF | CD47, CLTA, FCGR2A | ENPP2 55/4885KDM4E 2719/4885ALDH1A1 2153/4885 |
| US-20240228478-A1 | COMPOUNDS AND METHODS OF USE | F12, C1R, ABCG2 | ENPP2 1876/4885KDM4E 3895/4885ALDH1A1 128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.